Global Markets
Home›Global Markets›China›China pharma contractors show resilience amid US suppl…
China pharma contractors show resilience amid US supply-chain pressure
Genscript Biotech lifted full-year guidance for its life science services segment to 25% to 30%, while its CFO said AI-driven drug discovery orders are expected to double in the second half.
China’s pharmaceutical contractors are showing resilience as the US seeks to reduce reliance on Chinese supply chains, with industry resistance and cost advantages helping support investor sentiment, according to SCMP Economy.
Genscript Biotech raised its full-year guidance for its life science service segment, covering DNA, RNA and peptide synthesis tools alongside protein production services, to a range of 25% to 30% for the full year. The segment accounts for most of its revenue.
The company also said AI-driven drug discovery orders are expected to double in the second half and remain strong over the next several years, as Chief Financial Officer Phil Zhou said on an earnings call.